While increasingly depending on innovation-led growth to propel performance, Sun Pharmaceutical Industries anticipates that its US generics business will stabilize as manufacturing compliance improves and new product releases resume. According to management, as important facilities regain full compliance, pressure on the US generics portfolio, which has experienced price decline and regulatory restrictions, should lessen.
Addressing analysts after the December quarter results, Richard Ascroft, CEO for North America, said recovery in generics will follow the resolution of production concerns, permitting fresh releases. In Q3FY26, Sun Pharma’s US formulations sales climbed marginally by 0.6 per cent to $477 million, with novel medicines offsetting lower generics. The US accounted for around 27.5 per cent of consolidated revenue.
The company is intensifying two specialty launches in the US: LEQSELVI for severe alopecia areata and UNLOXCYT, an immunotherapy for advanced cutaneous squamous cell carcinoma, both of which have received positive early response from doctors.
With continuing clinical trials in diabetes and other metabolic illnesses, Sun Pharma is also bolstering its worldwide innovation pipeline. The anticipated day-one launch of generic semaglutide upon patent expiration in India, for which regulatory permissions are currently in place, is a significant near-term growth driver.
The management reaffirmed a methodical approach to acquisitions, emphasizing long-term strategic fit and organic growth.
